Epigenetics in Cardiac Hypertrophy and Heart Failure

JACC Basic Transl Sci. 2019 Dec 23;4(8):976-993. doi: 10.1016/j.jacbts.2019.05.011. eCollection 2019 Dec.

Abstract

Heart failure (HF) is a complex syndrome affecting millions of people around the world. Over the past decade, the therapeutic potential of targeting epigenetic regulators in HF has been discussed extensively. Recent advances in next-generation sequencing techniques have contributed substantial progress in our understanding of the role of DNA methylation, post-translational modifications of histones, adenosine triphosphate (ATP)-dependent chromatin conformation and remodeling, and non-coding RNAs in HF pathophysiology. In this review, we summarize epigenomic studies on human and animal models in HF.

Keywords: BET, bromodomain; EZH2, Enhancer of zeste homolog 2; HAT, histone acetyltransferase; HDAC, histone deacetylase; HDM, histone demethylase; HF, heart failure; HMT, histone methyltransferase; PRC2, polycomb repressor complex 2; PTMs, post-translational modifications; TAD, topologically associating domains; TMAO, trimethylamine N-oxide; cardiac hypertrophy; epigenetics; heart failure; lnc-RNAs, long ncRNAs.

Publication types

  • Review